Drugs that contain Tapinarof

1. Drug name - VTAMA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10647649 DERMAVANT SCI Process for preparing tapinarof
Nov, 2038

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10426743 DERMAVANT SCI Topical pharmaceutical compositions
May, 2036

(13 years from now)

US11458108 DERMAVANT SCI
May, 2036

(13 years from now)

US10195160 DERMAVANT SCI Topical pharmaceutical compositions
May, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 23, 2027

Market Authorisation Date: 23 May, 2022

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: CREAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% CREAM;TOPICAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in